NCT05636579 - Study to Assess Safety and Tolerability of Multiple Doses of EO2002 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

July 30, 2025

Study Completion Date

December 31, 2025

Conditions

Corneal EdemaCorneal Endothelial DystrophyEndothelial DysfunctionFuchs DystrophyFuchs' Endothelial DystrophyBullous KeratopathyPseudophakic Bullous KeratopathyCorneal Edema Pseudophakic

Interventions

BIOLOGICAL

EO2002

Intracameral injection of magnetic human corneal endothelial cells (EO2002)

DRUG

Ripasudil

Daily use of Ripasudil drops

Trial Locations (1)

04030

RECRUITING

Asociacion para Evitar la Ceguera en Mexico, Mexico City